BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa, fo...
AB-BIOBETTER, led by Bio-Sourcing, to pioneer development of new oral formulation of adalimumab for inflammatory bowel diseases; offering patient...
Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong ...
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-m...
Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clini...
YGION Biomedical GmbH, a company dedicated to developing individualized neoantigen-based cancer vaccines, today announced the completion of a Series A fina...
Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more eff...
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by...
Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical de...
Exergen Corporation, a leader in temperature measurement technology, has filed a lawsuit against Baxter International Inc. in the United States District Co...
Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-R...
The facilities, located in Solna, Stängnäs, Höganäs, Karlskoga, and Uppsala OTC Development in Sweden, Pessac in France...
Genmab A/S (Nasdaq: GMAB) and ProfoundBio, Inc. have officially announced a definitive agreement for Genmab's acquisition of ProfoundBio in an all-cash dea...
“The acquisition of CymaBay brings us a potential best-in-disease therapy that could transform the treatment landscape for people wit...
© 2025 Biopharma Boardroom. All Rights Reserved.
